Siemens Healthineers Net Profit Rises as Order Momentum Continues
By Nina Kienle
Siemens Healthineers posted a rise in net profit in its third quarter after continued positive order momentum, and reiterated its guidance for the year.
The German healthcare company on Wednesday said it made a net profit of 469 million euros ($507.3 million) for the quarter ended June, up from EUR445 million in the same period of the prior year.
Revenue rose to EUR5.42 billion from EUR5.20 billion, despite continuing order delays in China, the company said.
Adjusted earnings before interest and taxes rose to EUR825 million from EUR758 million, while the margin expanded to 15.2% from 14.6%.
Analysts had expected net profit, revenue and operating profit at EUR460.4 million, EUR5.53 billion and EUR699.7 million, respectively, according to consensus estimates provided by Visible Alpha.
For 2024, the company stuck to its outlook, expecting comparable revenue growth of between 4.5% and 6.5%, and adjusted earnings per share of between EUR2.10 and EUR2.30.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
July 31, 2024 01:53 ET (05:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks